Thionamides in the treatment of Graves' disease
- Douglas S Ross, MD
Douglas S Ross, MD
- Section Editor — Thyroid Disease
- Professor of Medicine
- Harvard Medical School
The thionamides, methimazole, carbimazole, and propylthiouracil (PTU), are effective treatment of patients with Graves' hyperthyroidism. They are actively transported into the thyroid gland where they inhibit both the organification of iodine to tyrosine residues in thyroglobulin and the coupling of iodotyrosines (figure 1) . (See "Pharmacology and toxicity of thionamides".)
The clinical use and efficacy of the thionamides in the treatment of Graves' hyperthyroidism will be reviewed here; the pharmacology and toxicity of these drugs, as well as other treatment options for Graves' hyperthyroidism, are reviewed separately. (See "Pharmacology and toxicity of thionamides" and "Graves' hyperthyroidism in nonpregnant adults: Overview of treatment".)
Thionamides are often started in patients with Graves' hyperthyroidism to attain a euthyroid state rapidly in preparation for radioiodine therapy or thyroidectomy. However, patients who want to avoid or defer ablative therapy with radioiodine or surgery can continue the thionamide for prolonged periods. (See "Graves' hyperthyroidism in nonpregnant adults: Overview of treatment", section on 'Choice of therapy'.)
Although hyperthyroidism can almost always be controlled as long as the drug is taken, overall, only approximately 20 to 30 percent of patients achieve a permanent remission. This estimate includes patients with severe disease in whom remissions are unlikely, as well as patients with mild disease in whom remission rates may be as high as 75 percent. (See 'Rate of prolonged remission' below.)
Patients treated with thionamides take three to eight weeks to become euthyroid because they block new hormone synthesis, and any already formed thyroxine (T4) and triiodothyronine (T3) stored in the colloid must be secreted and metabolized for clinical improvement to occur.
- Cooper DS. Antithyroid drugs. N Engl J Med 2005; 352:905.
- Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26:1343.
- He CT, Hsieh AT, Pei D, et al. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism. Clin Endocrinol (Oxf) 2004; 60:676.
- Imseis RE, Vanmiddlesworth L, Massie JD, et al. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab 1998; 83:685.
- Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease. Thyroid 2004; 14:525.
- Nakamura H, Noh JY, Itoh K, et al. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2007; 92:2157.
- Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab 2009; 94:1881.
- Bahn RS, Burch HS, Cooper DS, et al. The Role of Propylthiouracil in the Management of Graves' Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 2009; 19:673.
- Nabil N, Miner DJ, Amatruda JM. Methimazole: an alternative route of administration. J Clin Endocrinol Metab 1982; 54:180.
- Walter RM Jr, Bartle WR. Rectal administration of propylthiouracil in the treatment of Graves' disease. Am J Med 1990; 88:69.
- Hodak SP, Huang C, Clarke D, et al. Intravenous methimazole in the treatment of refractory hyperthyroidism. Thyroid 2006; 16:691.
- Gregoire G, Aris-Jilwan N, Ninet B, et al. Intravenous administration of propylthiouracil in treatment of a patient with Graves' disease (abstract). 77th Annual Meeting, The Endocrine Society, 1995, Abstract P3-464.
- Jansson R, Dahlberg PA, Lindström B. Comparative bioavailability of carbimazole and methimazole. Int J Clin Pharmacol Ther Toxicol 1983; 21:505.
- Benker G, Vitti P, Kahaly G, et al. Response to methimazole in Graves' disease. The European Multicenter Study Group. Clin Endocrinol (Oxf) 1995; 43:257.
- Shiroozu A, Okamura K, Ikenoue H, et al. Treatment of hyperthyroidism with a small single daily dose of methimazole. J Clin Endocrinol Metab 1986; 63:125.
- Sato S, Noh JY, Sato S, et al. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism. Thyroid 2015; 25:43.
- Takamatsu J, Hosoya T, Naito N, et al. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves' disease. J Clin Endocrinol Metab 1988; 66:147.
- Chen JJ, Ladenson PW. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease. J Clin Endocrinol Metab 1986; 63:102.
- Ross DS, Daniels GH, Gouveia D. The use and limitations of a chemiluminescent thyrotropin assay as a single thyroid function test in an out-patient endocrine clinic. J Clin Endocrinol Metab 1990; 71:764.
- Boelaert K, Maisonneuve P, Torlinska B, Franklyn JA. Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine. J Clin Endocrinol Metab 2013; 98:1869.
- Azizi F, Ataie L, Hedayati M, et al. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol 2005; 152:695.
- Villagelin D, Romaldini JH, Santos RB, et al. Outcomes in Relapsed Graves' Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment. Thyroid 2015; 25:1282.
- Abraham P, Avenell A, McGeoch SC, et al. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev 2010; :CD003420.
- Allannic H, Fauchet R, Orgiazzi J, et al. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990; 70:675.
- Maugendre D, Gatel A, Campion L, et al. Antithyroid drugs and Graves' disease--prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf) 1999; 50:127.
- Konishi T, Okamoto Y, Ueda M, et al. Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. Endocr J 2011; 58:95.
- Carella C, Mazziotti G, Sorvillo F, et al. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 2006; 16:295.
- Maugendre D, Massart C. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay. Clin Endocrinol (Oxf) 2001; 54:89.
- Törring O, Tallstedt L, Wallin G, et al. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 1996; 81:2986.
- Brownlie BE, Legge HM. Thyrotropin results in euthyroid patients with a past history of hyperthyroidism. Acta Endocrinol (Copenh) 1990; 122:623.
- Rotondi M, Cappelli C, Pirali B, et al. The effect of pregnancy on subsequent relapse from Graves' disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab 2008; 93:3985.
- Solomon BL, Evaul JE, Burman KD, Wartofsky L. Remission rates with antithyroid drug therapy: continuing influence of iodine intake? Ann Intern Med 1987; 107:510.
- Codaccioni JL, Orgiazzi J, Blanc P, et al. Lasting remissions in patients treated for Graves' hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease. J Clin Endocrinol Metab 1988; 67:656.
- Struja T, Fehlberg H, Kutz A, et al. Can we predict relapse in Graves' disease? Results from a systematic review and meta-analysis. Eur J Endocrinol 2017; 176:87.
- Kawai K, Tamai H, Matsubayashi S, et al. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs. Clin Endocrinol (Oxf) 1995; 43:551.
- Michelangeli V, Poon C, Taft J, et al. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid 1998; 8:119.
- Vitti P, Rago T, Chiovato L, et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997; 7:369.
- Glinoer D, de Nayer P, Bex M, Belgian Collaborative Study Group on Graves' Disease. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 2001; 144:475.
- Tada H, Mizuta I, Takano T, et al. Blocking-type anti-TSH receptor antibodies and relation to responsiveness to antithyroid drug therapy and remission in Graves' disease. Clin Endocrinol (Oxf) 2003; 58:403.
- Eckstein AK, Lax H, Lösch C, et al. Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol (Oxf) 2007; 67:607.
- Allahabadia A, Daykin J, Holder RL, et al. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 2000; 85:1038.
- Romaldini JH, Bromberg N, Werner RS, et al. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism. J Clin Endocrinol Metab 1983; 57:563.
- Reinwein D, Benker G, Lazarus JH, Alexander WD. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment. J Clin Endocrinol Metab 1993; 76:1516.
- Mashio Y, Beniko M, Matsuda A, et al. Treatment of hyperthyroidism with a small single daily dose of methimazole: a prospective long-term follow-up study. Endocr J 1997; 44:553.
- Page SR, Sheard CE, Herbert M, et al. A comparison of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism. Clin Endocrinol (Oxf) 1996; 45:511.
- Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab 1987; 64:1241.
- Kaguelidou F, Alberti C, Castanet M, et al. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 2008; 93:3817.
- Léger J, Gelwane G, Kaguelidou F, et al. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study. J Clin Endocrinol Metab 2012; 97:110.
- Takaichi Y, Tamai H, Honda K, et al. The significance of antithyroglobulin and antithyroidal microsomal antibodies in patients with hyperthyroidism due to Graves' disease treated with antithyroidal drugs. J Clin Endocrinol Metab 1989; 68:1097.
- Kraiem Z, Baron E, Kahana L, et al. Changes in stimulating and blocking TSH receptor antibodies in a patient undergoing three cycles of transition from hypo to hyper-thyroidism and back to hypothyroidism. Clin Endocrinol (Oxf) 1992; 36:211.
- CLINICAL USE
- INITIATION OF THERAPY
- Choice of drug
- Pretreatment evaluation
- APPROACH TO STOPPING THERAPY
- Duration of therapy
- Evaluation prior to stopping therapy
- Monitoring for recurrence
- Time course of relapse
- Treatment of recurrence
- Rate of prolonged remission
- Predictors of remission
- - Clinical factors
- - Role of thionamide dose
- - Role of combination therapy with T4
- Mechanism of remission
- SOCIETY GUIDELINE LINKS
- INFORMATION FOR PATIENTS
- SUMMARY AND RECOMMENDATIONS